|
|
Article: New Drugs From Servier/Novartis, Sanofi-Aventis and NeuroSearch/GlaxoSmithKline for Treatment of Major Depressive Disorder Will Achieve More Than $4 Billion in Sales by 2016.
- Article from:
- PR Newswire
- Article date:
- December 5, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Overall Sales Will Remain Static Owing to Generic Erosion of Currently Available Therapies, According to a New Report from Decision Resources
WALTHAM, Mass., Dec. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that new therapies with novel mechanisms of action from Servier/Novartis, Sanofi-Aventis, and NeuroSearch/GlaxoSmithKline will achieve more than $4 billion in sales in the major depressive disorder drug market.
The new Pharmacor report entitled Major Depressive Disorder finds that the launches of Servier/Novartis's agomelatine, Sanofi-Aventis's ...